Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1109002/full |
| _version_ | 1828061587159646208 |
|---|---|
| author | Mingming Fan Mingming Fan Huijuan Xiao Huijuan Xiao Dingyun Song Lili Zhu Jie Zhang Xinran Zhang Xinran Zhang Jing Wang Huaping Dai Chen Wang Chen Wang Chen Wang |
| author_facet | Mingming Fan Mingming Fan Huijuan Xiao Huijuan Xiao Dingyun Song Lili Zhu Jie Zhang Xinran Zhang Xinran Zhang Jing Wang Huaping Dai Chen Wang Chen Wang Chen Wang |
| author_sort | Mingming Fan |
| collection | DOAJ |
| first_indexed | 2024-04-10T22:16:15Z |
| format | Article |
| id | doaj.art-527e9762d71f46a7a0eaed71a55ee671 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T22:16:15Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-527e9762d71f46a7a0eaed71a55ee6712023-01-18T07:52:24ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-01-011310.3389/fphar.2022.11090021109002Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarizationMingming Fan0Mingming Fan1Huijuan Xiao2Huijuan Xiao3Dingyun Song4Lili Zhu5Jie Zhang6Xinran Zhang7Xinran Zhang8Jing Wang9Huaping Dai10Chen Wang11Chen Wang12Chen Wang13Department of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, ChinaDepartment of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, Chinahttps://www.frontiersin.org/articles/10.3389/fphar.2022.1109002/fullsilicosispulmonary fibrosisAKEX0011macrophage polarizationpirfenidone |
| spellingShingle | Mingming Fan Mingming Fan Huijuan Xiao Huijuan Xiao Dingyun Song Lili Zhu Jie Zhang Xinran Zhang Xinran Zhang Jing Wang Huaping Dai Chen Wang Chen Wang Chen Wang Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization Frontiers in Pharmacology silicosis pulmonary fibrosis AKEX0011 macrophage polarization pirfenidone |
| title | Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization |
| title_full | Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization |
| title_fullStr | Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization |
| title_full_unstemmed | Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization |
| title_short | Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization |
| title_sort | corrigendum a novel n arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ask1 p38 pathway and regulating macrophage polarization |
| topic | silicosis pulmonary fibrosis AKEX0011 macrophage polarization pirfenidone |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1109002/full |
| work_keys_str_mv | AT mingmingfan corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT mingmingfan corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT huijuanxiao corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT huijuanxiao corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT dingyunsong corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT lilizhu corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT jiezhang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT xinranzhang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT xinranzhang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT jingwang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT huapingdai corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT chenwang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT chenwang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization AT chenwang corrigendumanovelnarylpyridonecompoundalleviatestheinflammatoryandfibroticreactionofsilicosisbyinhibitingtheask1p38pathwayandregulatingmacrophagepolarization |